Shopping Cart
- Remove All
Your shopping cart is currently empty
Brazikumab (AMG 139) is a humanized antibody targeting IL-23 by binding to the P19 subunit. It is a selective IL23p19 antagonist and can be used in Crohn's disease research.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $197 | In Stock | |
| 5 mg | $516 | In Stock | |
| 10 mg | $828 | In Stock | |
| 25 mg | $1,230 | In Stock | |
| 50 mg | $1,650 | In Stock |
| Description | Brazikumab (AMG 139) is a humanized antibody targeting IL-23 by binding to the P19 subunit. It is a selective IL23p19 antagonist and can be used in Crohn's disease research. |
| Targets&IC50 | IL-23:0.138 nM (Kd) |
| In vitro | Brazikumab is a human IgG2 monoclonal antibody that binds to the p19 subunit with high affinity and has a KD of 0.138 nM against human IL-23. Brazikumab inhibits the binding of recombinant and natural IL-23 to receptors that are stably expressed in COS cells with IC50 of 188 and 284 pM, respectively. Brazikumab inhibits in vitro production of IFN-γ in NK cells stimulated by human natural or recombinant IL-23 (bound to IL-18) with IC50 of 238 and 93 pM, respectively. [1] |
| Synonyms | MEDI2070, MEDI 2070, AMG139, AMG 139 |
| Cas No. | 1610353-18-8 |
| Color | Transparent |
| Appearance | Liquid |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.